Fig. 9: Concept for clinical trial of radioprotected CAR T and RT.
From: Enhancing adoptive cell therapy: future strategies for immune cell radioprotection in neuro-oncology
Patients with suspected glioma are recruited to the trial. Patients undergo standard-of-care surgical resection followed by radiation therapy. PBMCs are collected and manufactured into CAR T cells including the radioprotector(s) identified here. CAR T cells are re-infused by day 56, providing time for CAR manufacturing but delivering CAR T early in the RT course when immunogenicity may be highest. Concurrent standard-of-care temozolomide may be given or omitted depending on rapid tumor molecular analysis.
